论文部分内容阅读
目的探讨纳络酮与川芎嗪联合治疗肺源性心脏病(肺心病)并呼吸衰竭的临床疗效。方法选取本院肺心病并呼吸衰竭患者80例,随机分为研究组和对照组,各40例,对照组给予常规治疗;研究组在此基础上给予纳络酮与川芎嗪联合治疗,比较两组的临床疗效。结果治疗后研究组治疗总有效率及血气分析指标均明显优于对照组,差异有统计学意义(P<0.05)。结论纳络酮与川芎嗪治疗肺心病合并呼吸衰竭临床疗效显著,安全可靠,值得临床应用。
Objective To investigate the clinical efficacy of naloxone combined with ligustrazine in the treatment of pulmonary heart disease (pulmonary heart disease) and respiratory failure. Methods 80 patients with pulmonary heart disease and respiratory failure in our hospital were randomly divided into study group and control group, 40 cases in each group. The control group was given routine treatment. On the basis of this study, the study group was given naloxone combined with ligustrazine, Group clinical efficacy. Results After treatment, the total effective rate of the study group and blood gas analysis indicators were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Naloxone and ligustrazine treatment of pulmonary heart disease with respiratory failure clinical efficacy was significant, safe and reliable, it is worth clinical application.